Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.41 |
| ▸ | VEGFA | P15692 | 4/20 | 0.41 |
| ▸ | FLT1 | P17948 | 4/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485031 | 0.89 | TSHR (0.49) | ALOX5EGLN1VEGFAFLT1CHEK1 | |
| SCHEMBL3485259 | 0.88 | CHEK2 (0.47) | ALOX5EGLN1VEGFAFLT1CHEK1 | |
| SCHEMBL3484861 | 0.88 | CHEK1 (0.43) | ALOX5EGLN1VEGFAFLT1CHEK1 | |
| SCHEMBL3485346 | 0.87 | ALOX5 (0.42) | ALOX5EGLN1VEGFAFLT1CHEK1 | |
| SCHEMBL3484492 | 0.85 | ALDH1A1 (0.46) | ALOX5EGLN1VEGFAFLT1CHEK1 | |
| SCHEMBL3484720 | 0.83 | ALOX5 (0.45) | ALOX5CHEK1CHEK2TSHRTDP1 | |
| SCHEMBL14331204 | 0.80 | EGLN1 (0.57) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL3484271 | 0.80 | EGLN1 (0.62) | EGLN1VEGFAFLT1EGLN3 | |
| SCHEMBL3485378 | 0.79 | ALOX5 (0.43) | ALOX5EGLN1VEGFAFLT1CHEK1 | |
| SCHEMBL3485344 | 0.78 | EGLN1 (0.58) | EGLN1VEGFAFLT1EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160009648-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2016-01-14 | — | — | US | claimed |
| US-8343952-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS INC. (US) | 2013-01-01 | — | — | US | claimed |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009648-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | ALOX5 624/4885EGLN1 6/4885VEGFA 117/4885 |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | ALOX5 624/4885EGLN1 6/4885VEGFA 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.